Emma considering selling Respiratory Biologics Business

Discussion in 'GlaxoSmithKline' started by anonymous, Apr 4, 2018 at 11:20 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Reliable source at headquarters has confirmed that Emma is watching the sales of NUCALA. If they do not grow or start to significantly slip, action will be taken. Most likely second half of this year.
     

  2. anonymous

    anonymous Guest

    HA HA HA HA HA HA!!!!!!!! "A reliable source". HA HA HA HA HA HA!!!!! You're killing me smalls! Whoo! "reliable source". That's rich!
     
  3. anonymous

    anonymous Guest

    +1. And best of the best at GSK means those who have hung around the longest. The best of the best already left when patient first started.
     
  4. anonymous

    anonymous Guest

    MedImmune is going all out to hire the best reps. If it weren’t for non compete clause I would be there now. Our ship is sinking and we are stuck!
     
  5. anonymous

    anonymous Guest

    RUN RUN ! THE SKY IS FALLING ! He is saying. " Don't be alarmed ", said the wise old owl.
     
  6. anonymous

    anonymous Guest


    Emma is a loose cannon. She is fast moving and can be ruthless. Not a fan of hers.
     
  7. anonymous

    anonymous Guest

    Fasenra keeps picking away at our market share
     
  8. anonymous

    anonymous Guest

    Fasenra threat is real. Not sure Dupixent will give us much competition. Dosing every two weeks isn’t going to be an easy sell to physicians. Regeneron thinks the product will be self administered but this population is at a greater risk for anaphylactic reactions during administration. What really concerns me is that we haven’t broken the $500 million mark over two years after launch and now we are going to share our pie with others.
     
  9. anonymous

    anonymous Guest

    Enorasine is also a good product.
     
  10. anonymous

    anonymous Guest

    Priced too high.